Giving Patients the Power to Change Their Minds
NeonMind's Pharmaceutical Division is advancing two independent, psilocybin-based treatments for obesity that act on different mechanisms to promote weight management and induce lasting lifestyle changes.
NeonMind is developing the first and only novel psilocybin-based drug candidates targeting obesity. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind has an additional pipeline opportunity, NEO-002, which employs low-dose psilocybin to control appetite.